Gilead’s pricing on it’s new Hepatitis C drug, Sovaldi, has been outraging people on a global scale. Although recently approved in the United States, the U.S. has no effective or transparent way to understand the tradeoffs of a high priced drug versus health service savings. Many other major HTA agencies outside of the U.S. have yet to complete their assessments, what will their decisions be? Read more here. (Source: Context Matters, 5/5/14).
You are here: / / Sticker Shock In Drug Pricing – Are We Missing The Bigger Picture?